Summiting the Biosimilar Landscape: Practical Considerations for Biosimilar Evaluation
Originally presented at HOPA's 14th Annual Conference, March 2018.
The development of biosimilars is advancing rapidly, and the first biosimilar used to treat cancer in the United States has been approved. With more oncology biosimilar candidates in a robust pipeline, clinical pharmacists must have a comprehensive understanding of biosimilar development and stay abreast of biosimilar approvals for implementation in real-world clinical practice. This session will discuss the U.S. Food and Drug Administration’s framework for biosimilar development, with a focus on analytical testing; review currently approved biosimilars and biosimilar candidates in hematology and oncology in the United States; and identify barriers to biosimilar uptake. After completion of this session, clinical pharmacists should have the tools to facilitate proper discussions at pharmacy and therapeutic meetings and provide education to patients and healthcare providers in order to increase access to these lifesaving medications.
Lisa DiGrazia, PharmD BCOP BCPS
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.
This activity has been approved for .1 CEU
This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.
Release Date: September 26, 2018
Expiration Date: March 22, 2021